

REVIEW

Subject: Competition for the academic position "Professor" in the scientific specialty "Social Medicine and Organization of Health Care and Pharmacy", professional field: 7.3. Pharmacy, Field of Higher Education 7. Healthcare and Sports; for the needs of ESL "Social Pharmacy and Pharmacoconomics" at the Department of Physical Chemistry of the Faculty of Chemistry and Pharmacy at Sofia University "St. Kl. Ohridski ", announced in the State Newspaper, issue 30 / 15.04.2022

Reviewer: Prof. Zlatka Dimitrova Dimitrova, DSc.

ESL "Social Pharmacy and Pharmacoconomics", Department of Physical Chemistry, Faculty of Chemistry and Pharmacy, Sofia University "St. Kl. Ohridski ", elected a member of the scientific jury from the quota of Sofia University "St. Kl. Ohridski ", FChPh in execution of order №RD 38-237 / 16.05.2022 of the Rector of Sofia University "St. Kl. Ohridski " prof. DPhSc Anastas Gerdzhikov.

1. General presentation of the procedure

1.1. Legal basis of the procedure

The competition for the academic position "professor" in a professional field 7.3. Pharmacy, scientific specialty "Social Medicine and Organization of Health Care and Pharmacy" for the needs of the Faculty of Chemistry and Pharmacy (FChPh), is on the proposal of the Faculty Council (FC) of the Faculty of Chemistry and Pharmacy and by decision of the Academic Council of Sofia University "St. Kliment Ohridski" and was announced in SN no. 30/15.04.2022

1.2. Participants in the competition

Documents for participation in the competition within the legal deadline were received from the only candidate - Assoc. Prof. Emil Ivanov Hristov, Ph.D., currently a lecturer/ Assoc. professor/ at the Faculty of Chemistry and Pharmacy at Sofia University. The set of submitted documents and the attached electronic copies are prepared in accordance with the requirements of the relevant regulations for this procedure- The Academic Staff Development Act (ASDA), the Regulations for the Implementation of the Academic Staff Development Act (RIASDA) and the current institutional Regulations on the terms and conditions for acquiring scientific degrees and holding academic positions at Sofia University "St. Kliment Ohridski ".

1.3. Eligibility of candidates. Pursuant to Article 56 of the Regulations for the Implementation of the Law on the Development of Academic Staff in the Republic of Bulgaria and Art. 109, para 2 of the Regulations for the conditions and the order for acquiring scientific degrees and holding academic positions in Sofia University "St. Kliment Ohridski ", the Rector of Sofia University "St. Kliment Ohridski " has appointed a Commission to review the documents and draw up a protocol for the admission or non-admission of candidates in the competition. Within the statutory term, the Commission on Documents has decided to admit to the competition the only candidate, Assoc. Prof. Emil Ivanov Hristov, Ph.D., and he has been notified.

The first meeting of the Scientific Jury was held on 22. 06.2022. Chairman of the Scientific Jury was elected, three reviewers were approved, and on the basis of the materials distributed a few days before the meeting to all members of the SJ, in accordance with

Article 109, paragraphs 5 and 6, in connection with paragraphs 1, 3 and 5 of the Rules on the terms and conditions for obtaining scientific degrees and holding academic positions at Sofia University "St. Kliment Ohridski ", the Scientific Jury unanimously accepted that the scientific production provided by the candidate Assoc. Prof. Dr. Emil Ivanov Hristov, for participation in the competition meets the minimum national requirements and the additional requirements of Sofia University" St. Kliment Ohridski "and in accordance with art. 109, para 4 admits it to scientific evaluation. The candidate has been notified in time, in writing, that he has been admitted to the evaluation on the merits of the competition.

2. General presentation of the candidate

2.1. Biographical data

Emil Ivanov Hristov was born on January 25, 1966 in the town of Pernik. He graduated medicine at the Medical University of Sofia in 1993. He holds 3 diplomas for a recognized specialty in "Internal Medicine" in 2000, "Clinical Pharmacology and Therapy" in 2000 and "Gastroenterology" in 2006 and 2 qualifications - Certificate of Recognition –“ Conventional Ultrasound - Abdominal Ultrasound and Superficial Structures - first level” 2008 and Certificate of recognized legal capacity “Conventional gastro-endoscopy with biopsy - first level” 2008. He works as an assistant, senior assistant and chief. assistant at the Hospital "St. Ivan Rilski "at the Medical University of Sofia. For 5 years he has been a Member of the Specialized Commission for Authorization of Clinical Trials in the Republic of Bulgaria under the Minister of Health. From 13.04.2004 to 13.04.2009 he is the Executive Director of the Executive Agency for Medicines at the Ministry of Health. He was a Member of the National Council on Drugs at the Council of Ministers, Chairman of the Pharmacopoeia Committee of the Republic of Bulgaria under the Minister of Health, Observer and Member of the Management Board of the European Medicines Agency (representative of the Republic of Bulgaria), Member of the Group of Heads of Medicines Agencies in the EU (representative of the Republic of Bulgaria), Member of the Pharmaceutical Committee of the European Commission (representative of the Republic of Bulgaria). Since 2010 he has been working as an expert in Pharmadweiss, LLC (Limited Liability Company), Sofia - pharmaceutical sector. In 2013 he successfully defended his dissertation at the Faculty of Pharmacy at the Medical University of Plovdiv and since November 2014 he held the academic position of "Associate Professor" in "Social Medicine and Organization of Health Care and Pharmacy" in the professional field 7.3. pharmacy in FChPh at Sofia University "St. Kl. Ohridski ". In 2015-16 he was a member of the Standing Committee on Health and Sports at the National Agency for Evaluation and Accreditation. During the period 2017-2018 is an External Expert at the HTA Commission at the NCPHA. He is a member of the Pharmacy Council - an advisory body to the Dean of the FChPh.

3. Evaluation of the candidate

The evaluation of the candidate was performed in accordance with the requirements of the Academic Staff Development Act in the Republic of Bulgaria, the Regulations for implementation of the Academic Staff Development Act in the Republic of Bulgaria and the Regulations on the terms and conditions for obtaining scientific degrees and holding academic positions, Sofia University "St. Kliment Ohridski "according to the following criteria:

Criterion №1: Presence of acquired educational and scientific degree "doctor", which for the specialties of the regulated professions must be from the same specialty.

The candidate presents a diploma for awarded educational and scientific degree "Doctor" in the scientific specialty "Social Medicine and Organization of Healthcare and Pharmacy",

issued by MU-Plovdiv, based on a dissertation on "Analysis of some regulatory aspects of drug safety of biotechnological, high - tech medicinal products and new active substances ". The scientific specialty of the candidate is identical to the scientific specialty for which the competition was announced.

Criterion №2: Have held the academic position of "Associate Professor" at the same or another higher education institution or research organization for not less than two academic years or not less than five years, or: (a) have been lecturers, including part-time lecturers, or members of a research team at the same or another higher education institution or scientific organization, or (b) have been practitioners and have proven achievements in their field.

The candidate presents a certificate № SU-181 / 5.11.2014, which with a decision of the FC of the FChPh he was awarded a diploma for the academic position of "Associate Professor", as of 1.11.2014, which position he still holds in the Educational and Research Laboratory "Social Pharmacy and Pharmacoeconomics", at the Department of Physical Chemistry of the Faculty of Chemistry and Pharmacy, Sofia University "St. Kliment Ohridski" / 7y 6m /. Evidence materials include employment record book and Certificate No. 93 / 4.05.2022 from the Human Resources Department of Sofia University.

Criterion №3: To have submitted a published monographic work or equivalent publications in specialized scientific journals, which do not repeat those presented for the educational and scientific degree "Doctor", the scientific degree "Doctor of Science" and for the academic position "Associate Professor ".

Annex 2 presents 10 scientific publications (№№ 1-10 out of 27), which are referenced and indexed in world-famous databases with scientific information equivalent to a monograph. The topic that unites them, in my opinion, I would formulate as follows: Evaluation of new health technologies, incl. biological and biosimilar medicinal products and their rational use in rheumatology. I recommend Assoc. Prof. Hristov to reflect the results of these studies in the near future in an extremely useful monograph for doctors, students and PhD students.

Criterion №4: To have presented other original research papers, publications, inventions and other scientific and applied scientific works, which are evaluated as a whole

The candidate, Assoc. Prof. Dr. Emil Ivanov Hristov, Ph.D. presents its scientific production in 3 types of lists, prepared by sections, in accordance with the latest amendments in ASDA and RIASDA in Republic of Bulgaria:

- a) List of the overall scientific production of Assoc. Prof. Dr. Emil Hristov, Ph.D.
- b) List of publications of Assoc. Prof. Dr. Emil Hristov, PhD for participation in the competition (2017-2022)
- c) List of publications of Assoc. Prof. Dr. Emil Hristov, PhD for participation in the competition (2014-2022)

I accept the third list of publications of Assoc. Prof. Dr. Emil Hristov, PhD for participation in the competition 2014 - 2022 when writing this review, because it includes the scientific publications of the candidate after holding the academic position of "Associate Professor".

The report of the applicant for compliance with the minimum national requirements is also prepared on the basis of this list / 2014-2022 /

The candidate has submitted a declaration that the scientific papers, citations and other evidence on the individual scientometric indicators in the submitted report for implementation of the minimum national requirements under Art. 2b of the ASDA in the Professional Field 7.3 Pharmacy, not used by him for obtaining the educational and scientific

degree "Doctor" and for holding the academic position "Associate Professor" in the same professional field or to an academic position in another professional field.

The scientific production of the candidate covers a wide range of scientific specialties "Social Medicine and the organization of healthCare and pharmacy", and can be divided into, in my opinion, in the following areas:

1. Medicinal use and rational pharmacotherapy of socially significant diseases;

The topic of rational pharmacotherapy with biological products is present here in 8 scientific publications in scientific journals, referenced and indexed in world-famous databases of scientific information. This shows that Assoc. Prof. Hristov has deepened and expanded his research in this area after his election as an associate professor, incl. has successfully defended a PhD student under his scientific guidance on "Health-related quality of life in patients with vasculitis associated with antineutrophil cytoplasmic antibodies conducting biological treatment", FChPh, Sofia University "St. Kliment Ohridski", Tsvetomir Mario Deliiski / public defense of 18.03. 2022/. Two more of his full-time doctoral/PhD/ students are conducting their research in this field. The additional number of publications in his main scientific field is 16, of which 8- in scientific journals, referenced and indexed in world-famous databases of scientific information, 3- in chapters of collective monographs and 5- in journals with scientific review.

Scientific contributions: Presentations on drug usability and rational drug use at the macro and micro level and for specific therapeutic classes are presented. Most of the developments are of an original nature. /BMP for treatment of rheumatic diseases, arterial hypertension, etc./

Thus, for example: The use of BMP for the treatment of vasculitis is a therapeutic novelty and the timely initiation of treatment with biological drugs (Rituximab) leads to rapid control of clinical symptoms and entry into prolonged remission. Rituximab biologic treatment resulted in a significant improvement in health-related quality of life in over 75% of patients in the two main domains, physical and mental health, compared with patients in conventional treatment, where 75% of patients did not identify as healthy. The level of depression after treatment with a biological product is within the norm for the general population.

2. National drug policy and drug regulation;

In this scientific field the candidate has 24 publications, 5 of which have been published in scientific journals, referenced and indexed in world-famous databases of scientific information, 2 in chapters of collective monographs and 17 in journals with scientific review. One of his doctoral /PhD/ students Vladimir Antonov Atanasov has successfully defended his dissertation on "Study of the role and participation of pharmacists in clinical trials of MP", FChPh, Sofia University "St. Kliment Ohridski" / public defense on 23.03.2022 / and Anna Antonova Mitova has developed a thesis on "Regulatory requirements for determining the claims of cosmetic products" with supervisor Assoc. Prof. Dr. Emil Hristov, Ph.D., FChPh, Sofia University "St. Kliment Ohridski" / defense of the thesis - July 2022.

Scientific contributions: - Reports from national and international scientific forums are presented, which discuss practical steps in the implementation of European legislation in the field of drug regulation after the accession of the Republic of Bulgaria to the EU, tasks for regulators and the pharmaceutical industry and benefits for society as a whole.

- Developments on drug information, advertising of medicinal products and drug promotion in the light of the synchronization of Bulgarian practice with European law are also presented.

-The developments in the field of counterfeit medicines are of special importance, unique examples based on the Bulgarian experience are presented. Many of them are cited by the EC in the final document Impact Assessment, on the basis of which an EU Directive was created to counteract the spread of counterfeit drugs. Counterfeit medicines are one of the most significant threats to human health, and their entry into the market can lead to a loss of public confidence in both drug distribution systems and the public health system as a whole.

- In this regard, as of February 9, 2019. The directive requires the establishment of a national system for serialization and verification of medicinal products, which stores information on individual characteristics and allows the pharmacy to check each package given to a patient, as national systems connect to and operate in sync with the European system. The study found a high level of ignorance about upcoming innovations. Over 2/3 (78%) of the respondents do not know what are the practical challenges for their pharmacy practices.

- A comprehensive and exhaustive regulatory, scientific and practical analysis of the role and participation of the pharmacist in clinical trials of medicinal products in Bulgaria has been made. Basic guidelines and vision for the development of the profession of pharmacist and the need to acquire specific skills and competencies for participation and active role in conducting clinical trials have been formulated.

-The possibilities, advantages, disadvantages and "bottlenecks" in the implementation of pharmacists in conducting clinical trials of drugs in our country are presented and specific recommendations for the training of students in pharmacy are formulated.

3. Assessment of health technologies and pharmacoeconomics of new drugs;

A total of 8 articles have been published in this scientific field, of which 1 has been published in a scientific journal, referenced and indexed in world-famous databases with scientific information and 7 - in journals with scientific peer-review.

Scientific contributions: The entry into clinical practice of biological medicinal products (BIR) more than 10 years ago has raised complex regulatory issues as well as significant pharmacoeconomic concerns, as the costs of these therapies are many times higher than conventional ones. medical products. The periods of "data exclusivity" of BMP are in the process of expiration and are available on the market, etc. biosimilar products (BSPs). Their share is expected to gradually increase, leading to cost reductions and increased patient access to biological treatment.

-In one of the studies - retrospective observational study of data from the public registers of the EMA, National Council on Prices and Reimbursement of Medicinal Products and the NHIF in Bulgaria for the period 2015-2019, analyzed the availability and affordability of BSMP containing monoclonal antibodies and their usability in Bulgaria has been determined. The total costs for BMP for the period are BGN 682,330,385, of which the share of BMP in absolute value is only BGN 34,030,486, or 4.75%. The share of biosimilar Infliximab is BGN 31,405,331 or 92% of the total costs for UAVs, due to the lack of a reference Infliximab for the period 2015-2018, incl. Objectively, the conclusion is that the access of BSMPs to the Bulgarian market is still very limited. BSMPs are available and although they fall into a much lower price range, reference products are the preferred treatment. Probable reasons are the lack of national standards for the interchangeability of BMP with BSMPs, the distrust of prescribers to the so-called substitution therapies and aggressive drug promotion to medical professionals.

-Based on many foreign and Bulgarian literary sources are revealed trends in the treatment of cerebral aneurysms in recent decades abroad and in Bulgaria. This targeted study focuses on an important issue - modern treatment of cerebral aneurysms in our country. In practice, along with surgical treatment, endovascular treatment has entered and there is a tendency to increase its share.

-The first pharmacoeconomic evaluation of the two alternative modern therapeutic approaches was conducted and the results and costs of two PhEAs were measured and evaluated : costs-effectiveness and costs-utility.

-The developed methodological contribution has a developed methodology for conducting PhE assessment using two methods that measure the effectiveness in clinical units, taking into account the opinion of patients about their quality of life. Precisely performed sensitivity analyzes show stability in the variation of indicators, which is important in clinical and organizational terms.

4. Medicinal safety (pharmacovigilance) ;

There are 10 publications in this field, 2 of which have been published in scientific journals, referenced and indexed in world-famous databases with scientific information and 8- in journals with scientific review. The full doctoral/PhD/ student of Assoc. Prof. Hristov, Nedelko Assenov Nedelkov is developing a dissertation on "Special procedures for authorization of drugs and their impact on drug safety", FChPh, Sofia University "St. Kliment Ohridski".

Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality and contribute to the incidence of adverse events, leading to increased healthcare costs. Pharmacists have an important responsibility in monitoring the current safety of medicines.

Scientific contributions: -the fundamental aspects of drug safety, its scientific-regulatory significance and its practical application are considered and developed, on the one hand as obligations of state institutions and on the other- as commitments of the pharmaceutical industry, medical professionals and patients.

-The aim of several studies is to reveal the clinical responsibility of the pharmacist for the early detection of ADRs. Thus, for example, an anonymous survey conducted in three of the largest cities in Bulgaria among 421 pharmacists working in 102 open pharmacies and 3 hospital pharmacies shows that in Bulgaria there is a low rate of ADR reporting by pharmacists. Between January and June 2017, only 1.2% of all pharmacists reported ADRs, compared to about 70% of ADR reports submitted to the US MEDWATCH program by pharmacists, most of whom are from hospital pharmacies. Most of the surveyed pharmacists in our country unanimously share that they have not reported any observed ADRs either on the website of the Executive Agency for Medicines or through the Yellow Card system. . Insufficient readings can delay signal detection and cause underestimation of the problem. The effectiveness of the ADR monitoring and reporting program depends on the awareness of all health care providers.

- According to the latest amendments to the Law on Medicines in Human Medicine, patients can report side effects at any time to health professionals or the National Medicines Agency (BDA). A study conducted in the Plovdiv region shows that a larger percentage of patients would report ADRs mainly to doctors and other health professionals and are unaware of the existence of the yellow card. The results of the study reveal the need for closer links with patient organizations. When making direct contact with the patients themselves in pharmacies, it is recommended that they be trained in ADRs and their reporting.

-In a retrospective pharmacoepidemiological study to determine the type, frequency, severity and system-organ localization of adverse reactions occurring during treatment with biological medicinal products in patients with seropositive rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, 250 medical analyzes were registered records reflecting data for 715 patients followed for a 3-year period (June 2010 - June 2013). The conducted comparative analysis of the post-registration data obtained by the authors with the pre-registration data described in the approved Summary of Product Characteristics does not show significant differences.

-In a protocol conducted and after signed informed consent, single-center, observational, open, prospective, non-interventional, pharmacoepidemiological study of clinical series of cases of ADR in the Bulgarian population of patients with rheumatoid arthritis (RA), ankylosing spondylitis psoriatic arthritis (PsA), treated with BLP in the period March 2015 - October 2016, patients are treated with: Etanercept, Adalimumab, Golimumab, Certolizumab, Rituximab. It is obligatory that they have not carried out previous treatment with BMP. A very high incidence of ADR was found to be correspondingly higher than the pre-registration data for the analyzed BMPs. The most common reason for discontinuation of biological therapy in patients with inflammatory joint disease is the manifestation of ADR

5. Organization of health care - hospital management

7 published chapters in collective monographs are included in this direction. With them the total number of published chapters in monographs is 12. The participation of Assoc. Prof. Dr. Hristov in the monograph "Management of Hospital Resources. New Hospital Management" / 2018 /, co-authored by prominent specialists, theorists and researchers in the field of health management such as Prof. Dr. V. Borisov, DSci and others, is a recognition of competence and level of expertise of Assoc. Prof. Hristov on the issues of Rational Drug Therapy in the Hospital, National Drug Policy, the Drug Market in the World and Bulgaria, Management of the Hospital Pharmacy, etc. Another such example is the chapter "Hristov E., On drugs in physiological and pathological conditions in the new monograph of Prof. Zahari Krastev, D.Sc " Medicines and Clinic ", 2022.

6. History of pharmacy.

There are 5 publications in this field, of which 1 has been published in scientific journals, referenced and indexed in world-famous databases with scientific information and 4- in journals with scientific review.

Scientific contributions: -Political and economic and social differences between the studied Balkan countries / Bulgaria, Croatia, Serbia and Turkey / are the reason for a different start in the opening of the first modern pharmacies in the Middle Ages.

- In one of the oldest hospitals in the city of Kayseri in 1206 a pharmacy (Caesarea) was built. During the Ottoman period, the first pharmacy was opened, called the Two-Door Pharmacy (Iki Kapili Eczahane) in the Bahcekapi district of Istanbul in 1757. The first pharmacy of a Turkish pharmacist in Istanbul was registered in 1880 in the name of pharmacist Ahmet Hamdi Bey.

- A document from October 29, 1271 proves the existence of a pharmacy in Trogir, Croatia.

- The first private Serbian pharmacy of modern type was opened on April 30, 1830 in Belgrade by the Zemun pharmacist Mateja Ivanovic by decree of Prince Milos Obrenovic.

- Ludovico Melanesi graduated in pharmacy in Padua in 1855 and was elected a member of the Academy in Naples. In 1866 he founded a pharmacy in Vidin on a European model.

- The criteria for issuing authorizations for retail trade in medicinal products in pharmacies can be demographic and geographical. In 2010, the Court of Justice of the European Union

made clear its views on the positive effects of regulating the number of pharmacies. Approximately 98% of EU citizens can reach a pharmacy within 30 minutes.

- The idea of clinical pharmacy emerged with the development of modern hospitals in the United States in the 1920s among hospital pharmacists. Led by insightful and active leaders such as Harvey Whitey, Donald Franke, Donald Brody and others. Hospital pharmacists were the first to formulate the idea of clinical pharmacy, which dominated the pharmaceutical profession in the late twentieth century. With the development of clinical pharmacy emerged new concepts of pharmaceutical care and control of drug therapy for patients.

- After a thorough review and study of historical information and evidence, information was presented about three worthy Bulgarian women who turned their dream into reality - to be a master pharmacist and contributed to the development of pharmacy in our country.

Criterion № 5: The applicant must meet the minimum national requirements under Art. 2b, para. 2 and 3, respectively to the requirements under Art. 2b, para 5 of the Law for the development of the academic staff in the Republic of Bulgaria

The presented scientific production in quantitative and qualitative terms significantly exceeds the minimum national requirements for holding the academic position "Professor" in the field of higher education 7.0 "Health care and Sports", respectively Professional Field 7.3 "Pharmacy". The data are presented in tabular form by groups of indicators and in total. If not less than 550 points are needed, the presented scientific production by Assoc. Prof. Dr. Emil Ivanov Hristov, PhD, calculated according to the criteria is **2136.91 points**.

Criterion № 6: No plagiarism in scientific works has been proven in accordance with the law

I do not find information about proven plagiarism in the scientific works of the candidate Assoc. Prof. Dr. Emil Ivanov Hristov, Ph.D.

Additional criteria

Assoc. Prof. Dr. Emil Ivanov Hristov, Ph.D. is the only candidate in the competition, which circumstance excludes the need to analyze the additional criteria under Article 27, paragraph 4 of the Law on the Development of Academic Staff in the Republic of Bulgaria. However, I will dwell on them as well.

Criteria related to the educational activity:

The presented reports on the classroom and general study load of the lecturers in the Department of Physical Chemistry for the whole period show that Assoc. Prof. Hristov has an excessive workload, conducts lectures on compulsory subjects, conducts practical exercises on Social Pharmacy and pharmaceutical legislation, Pharmacoeconomics, teaches in English on the History of Pharmacy and Social Pharmacy and pharmaceutical legislation, training of Erasmus students in English in Pharmacoeconomics. He is responsible for the undergraduate internship of master pharmacists from 5th year, 10th semester and participates in semester and state exams. He is the author and co-author of the curricula in the compulsory disciplines for mag. pharmacists provided by ESL in Social Pharmacy and Pharmacoeconomics. He is the author of 3 new curricula for elective courses: "Clinical Medicine for Pharmacists" and "Fundamentals of Dermatology" for Masters in Pharmacy and "Cosmetic Legislation" for Masters in "Cosmetics and Household Chemistry" from 2019 and participates in teaching them. By order of the Minister of Health he was appointed a member of the state examination commission for recognition of the specialty in Clinical Pharmacology and Therapy / 2021-23 /.

He is a co-author of the textbook Fundamentals of Pharmacoeconomics, published in 2016 in the foreign publishing house Wolters Kluwer, with a foreign co-author-prof. Karen Rascati, who is also used in other schools in the country and 2 textbooks / 2006 /.

Criteria related to research:

He works well with students and PhD students and has 11 publications and reports published in scientific journals, referenced and indexed in world-renowned databases of scientific information, 24 publications and reports published in non-refereed journals with scientific review or published in edited collective volumes and 3 participations in projects.

Data for participation of Assoc. Prof. Hristov in five research projects are presented, 3 of which have been completed and 2 have been approved for funding in 2022; at 3 he is a leader and at 2 he is a participant. He has reviewed 18 publications in the journal Pharmacy and 4 in the European Journal of Hospital Pharmacy.

Assoc. Prof. Dr. Hristov has the following participations in clinical trials of medicinal products as a researcher: 2 participations in phase II / III clinical trials and 8 participations in bioequivalence clinical trials.

He is a member of authoritative professional organizations in the relevant scientific field: Bulgarian Society of Clinical Pharmacology and Therapy, Bulgarian Society of Gastroenterology and European Association for Clinical Pharmacology and Therapeutics.

Conclusion

The documentation submitted for the competition by Assoc. Prof. Dr. Emil Ivanov Hristov, Ph.D. fully meets the requirements of ASDA and RIASDA in RB and the Regulations on the terms and conditions for acquiring scientific degrees and holding academic positions at Sofia University "St. Kliment Ohridski" and in many of the evaluation criteria it far exceeds the nominal requirements regarding the teaching and research activities for holding the academic position of "professor".

The candidate is a well-established lecturer and respected scientist, has indisputable scientific achievements and authority in academia, has the necessary qualities to work with students, shows respect and collegiality, is able to work in a team and is a respected and sought-after expert with significant contributions in the field of social pharmacy, drug legislation, pharmacoeconomics and pharmacotherapy of socially significant diseases with biological products.

On this basis, I give a high positive assessment of the candidate, I will vote "Yes" and I strongly recommend to my deeply respected members of the Scientific Jury to choose Assoc. Prof. Dr. Emil Ivanov Hristov, Ph.D. for Professor of Social Medicine and Organization of Health Care and Pharmacy "in the professional field: 7.3. Pharmacy, Field of Higher Education 7. Health care and Sports for the needs of ESL" Social Pharmacy and Pharmacoeconomics "at the Department of Physical Chemistry of the Faculty of Chemistry and Pharmacy at Sofia University" St. Cl. Ohridski".

September 10, 2022
Sofia

Reviewer: 
/ Prof. Zl. Dimitrova, D.Sc./